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Impaired lung function is predictive of mortality1 and is the key diagnostic criterion for chronic obstructive pulmonary disease (COPD). Globally, COPD accounted for 2.9 million deaths in 
2016 (ref. 2), and is one of the key causes of both years of life lost and 
years lived with disability worldwide3. Determinants of maximally 
attained lung function and of lung function decline can influence 
the risk of developing COPD. Tobacco smoking is the single larg-
est risk factor for COPD, although other environmental exposures 
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Reduced lung function predicts mortality and is key to the diagnosis of chronic obstructive pulmonary disease (COPD). In a 
genome-wide association study in 400,102 individuals of European ancestry, we define 279 lung function signals, 139 of which 
are new. In combination, these variants strongly predict COPD in independent populations. Furthermore, the combined effect 
of these variants showed generalizability across smokers and never smokers, and across ancestral groups. We highlight bio-
logical pathways, known and potential drug targets for COPD and, in phenome-wide association studies, autoimmune-related 
and other pleiotropic effects of lung function–associated variants. This new genetic evidence has potential to improve future 
preventive and therapeutic strategies for COPD.
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and genetic makeup are important4,5. Genetic variants associated 
with lung function and COPD susceptibility can provide etiological 
insights, assisting with risk prediction as well as drug target identifi-
cation and validation6. Although there has been considerable prog-
ress in identifying genetic markers associated with lung function 
and risk of COPD4,7–19, seeking a high yield of associated genetic 
variants is key to progressing knowledge because (1) implication of 
multiple molecules in each pathway will be needed to build an accu-
rate picture of the pathways underpinning development of COPD; 
(2) not all proteins identified will be druggable and (3) combining 
information across multiple variants can improve prediction of 
disease susceptibility.
Through new detailed quality control and analyses of spirometric 
measures of lung function in the UK Biobank and expansion of the 
SpiroMeta Consortium, we undertook a large genome-wide asso-
ciation study (GWAS) of lung function. Our study entailed a near 
seven-fold increase in sample size over previous studies of similar 
ancestry to address the following aims: (1) to generate a high yield 
of genetic markers associated with lung function; (2) to confirm and 
fine-map previously reported lung function signals; (3) to investi-
gate the putative causal genes and biological pathways through 
which lung function–associated variants act, and their wider pleio-
tropic effects on other traits; and (4) to generate a weighted genetic 
risk score for lung function and test its association with COPD sus-
ceptibility in individuals of European and other ancestries.
Results
Discovery of 139 new signals for lung function. We increased 
the sample size available for the study of quantitative measures 
of lung function in UK Biobank by refining the quality control 
of spirometry based on recommendations of the UK Biobank 
Outcomes Adjudication Working Group (Supplementary Note). 
Genome-wide association analyses of forced expired volume in 
1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC were 
undertaken in 321,047 individuals in UK Biobank (Supplementary 
Table 1) and in 79,055 individuals from the SpiroMeta Consortium 
(Supplementary Tables 2 and 3). A linear mixed model imple-
mented in BOLT-LMM20 was used for UK Biobank to account for 
relatedness and fine-scale population structure (Methods). A total 
of 19,819,130 autosomal variants imputed in both UK Biobank 
and SpiroMeta were analyzed. Peak expiratory flow (PEF) was also 
analyzed genome-wide in UK Biobank and up to 24,218 samples 
from SpiroMeta. GWAS results in UK Biobank were adjusted for 
the intercept of linkage disequilibrium (LD) score regression21, 
but SpiroMeta and the meta-analysis were not, as intercepts were 
close to 1.00 (Methods). All individuals included in the genome-
wide analyses were of European ancestry (Supplementary Fig. 1 and 
Supplementary Note).
To maximize statistical power for discovery of new signals while 
maintaining stringent significance thresholds to minimize report-
ing of false positives, we adopted a study design incorporating 
both two-stage and one-stage approaches (Fig. 1). In the two-stage 
analysis, 99 new distinct signals, defined using conditional analy-
ses22, were associated with one or more traits at P < 5 × 10−9 (ref. 23) 
in UK Biobank and showed association (P < 10−3) with a consis-
tent direction of effect in SpiroMeta (tier 1 signals, Supplementary 
Fig. 2 and Supplementary Table 4). In the one-stage analysis, we 
meta-analyzed UK Biobank and SpiroMeta (up to 400,102 indi-
viduals), and identified 40 additional new distinct signals associ-
ated with one or more lung function traits reaching P < 5 × 10−9 
(Supplementary Fig. 2 and Supplementary Table 4) that were also 
associated with P < 10−3 separately in UK Biobank and in SpiroMeta, 
with consistent direction of effect (tier 2 signals). An additional 323 
autosomal signals were significantly associated with one or more lung 
function traits in the meta-analysis of UK Biobank and SpiroMeta 
(P < 5 × 10−9) and reached P < 10−3 for association in only one of 
UK Biobank or SpiroMeta (tier 3 signals, Supplementary Table 5). 
Analysis of chromosome X variants in 359,226 individuals (321,027 
UK Biobank and 38,199 SpiroMeta15) gave an additional five tier-3 
signals. Only the 139 signals meeting tier-1 and tier-2 criteria were 
followed up. The strength and direction of association of the sentinel 
variant (the variant in each signal with the lowest P value) for these 
139 new signals across all four lung function traits are shown in 
Fig. 2. Of the 139 signals, 131 were associated with at least two lung 
function traits at P < 10−3, 8 signals were unique to FEV1/FVC and 
no signals were unique to FEV1, FVC or PEF at this threshold.
We assessed whether any of these 139 signals associated with lung 
function could be driven via an underlying association with smok-
ing behavior (Methods). Only rs193686 (Supplementary Table 6) 
was associated with smoking behavior. Although rs193686 was asso-
ciated with smoking initiation (P = 9.18 × 10−6), the allele associated 
with smoking initiation was associated with increased lung func-
tion in never smokers (FEV1/FVC P = 5.28 × 10−10, Supplementary 
Table 7). Therefore, this signal was retained for further analysis.
A total of 279 signals of association for lung function. Of 157 pre-
viously published autosomal signals of association with lung func-
tion and COPD3,6–18, 142 were associated at P < 10−5 in UK Biobank 
(Methods, Supplementary Fig. 3 and Supplementary Table 8). Two 
sentinel variants (rs1689510 and rs11134789) were associated with 
smoking initiation (Supplementary Table 6), but were also associ-
ated with lung function in never smokers (Supplementary Table 7). 
SNP rs17486278 at CHRNA5 and SNP rs11667314 near CYP2A6 
were both associated with cigarettes per day (Supplementary 
Table 6); neither was significantly associated with lung func-
tion among never smokers and so both were excluded from fur-
ther analysis. This brings the total number of distinct signals of 
association with lung function to 279 (Supplementary Table 9). 
None of these variants showed interaction with ever-smoking 
status (P > 1.8 × 10−4, Methods and Supplementary Table 7). 
Using the effect estimates and allele frequencies and assuming a 
total heritability of 40% (refs. 24,25; Methods), we calculated that 
the 140 previously reported lung function signals showing asso-
ciation in this study (UK Biobank P < 10−5) explained 5.0%, 3.4%, 
9.2% and 4.5% of the estimated heritability of FEV1, FVC, FEV1/
FVC and PEF, respectively. The 139 new signals reported here 
explain an additional 4.3%, 3.3%, 3.9% and 3.3% of the estimated 
heritability, respectively.
Identification of putative causal genes. Bayesian refinement was 
undertaken for each signal, using the meta-analysis of UK Biobank 
and SpiroMeta, to identify the set of variants that were 99% prob-
able to contain the underlying causal variant (assuming the causal 
variant has been analyzed; Methods, Supplementary Table 10 and 
Supplementary Data 1 and 2).
To identify putative causal genes for each signal, we identified 
deleterious variants and variants associated with gene expression 
(expression quantitative trait loci, eQTLs) or protein levels (protein 
quantitative trait loci, pQTLs) within each 99% credible set for all 
new and previously reported signals outside the human leukocyte 
antigen (HLA) region (where extensive linkage disequilibrium 
makes individual signals complex to define) (Methods).
There were 25 SNPs, located in 22 unique genes, that were 
annotated as potentially deleterious (Methods and Supplementary 
Table 11). Among our new signals, there were ten variants anno-
tated as deleterious in nine different genes: DOCK9 (rs117633128), 
CEP72 (rs12522955), BCHE (rs1799807), DST (rs11756977), 
KIAA0753 (rs2304977 and rs9889363), LRRC45 (rs72861736), 
BTC (rs11938093), MAB21L4 (rs6709469) and IER5L (rs184457). 
Of these, the missense variant in BCHE (rs1799807) had the high-
est posterior probability (0.996) in its respective credible set, was 
low in frequency (minor allele frequency = 1.95%) and leads to an 
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amino acid change from aspartic acid to glycine, which affects the 
function of the encoded butyrylcholinesterase enzyme by alter-
ing substrate binding26. The two common missense variants in 
KIAA0753 were within the credible set of new signal rs4796334. 
KIAA0753, CEP72 and LRRC45 all encode proteins with a role in 
ciliogenesis or cilia maintenance27–31, and all are highly expressed in 
the airway epithelium32.
Variants in the 99% credible sets were queried in three eQTL 
resources to identify associations with gene expression in lung33–35 
(n = 1,111; Supplementary Table 12), blood36 (n = 4,896) and a sub-
set of Genotype-Tissue Expression (GTEx)37 tissues (maximum 
n = 388, Methods). The tissues included from GTEx were lung and 
blood, plus nine tissues containing smooth muscle (Methods). The 
latter were chosen based on previous reports of enrichment of lung 
function GWAS signals in smooth muscle–containing tissues18,38. 
We identified 88 genes, implicated by 58 of the 279 signals, for 
which the most significant SNP associated with expression of that 
gene in the respective eQTL resource was within one of the 99% 
credible sets (Supplementary Table 13).
We checked credible set variants for association with protein lev-
els in a pQTL study39 comprising SNP associations for 3,600 plasma 
proteins (Methods). We found five proteins with a sentinel pQTL 
contained within our lung function credible set: ECM1, THBS4, 
NPNT, C1QTNF5 and SCARF2 (Supplementary Table 14).
In total, 107 putative causal genes were identified (Table 1), 
among which we highlight 75 for the first time as putative causal 
genes for lung function (43 implicated by a new signal and 32 newly 
implicated by a previous signal18).
Pathway analysis. We tested whether these 107 putative causal 
genes were enriched in gene sets and biological pathways (Methods), 
and found an enrichment of genes in elastic fiber and extracellu-
lar matrix organization pathways, and a number of gene ontolo-
gies including gene sets relating to the cytoskeleton and processes 
involved in ciliogenesis (Supplementary Table 15). Although the 
enrichment in elastic fiber–related pathways is consistent with our 
previous study18, enrichment in these pathways was further sup-
ported in this analysis by two new genes, ITGAV (at a new signal) 
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Fig. 1 | Study design. Tier 1 signals had P <  5 ×  10−9 in UK Biobank and P <  10−3 in SpiroMeta with consistent direction of effect. Tier 2 signals had 
P <  5 ×  10−9 in the meta-analysis of UK Biobank and SpiroMeta with P <  10−3 in UK Biobank and P <  10−3 in SpiroMeta with consistent directions of effect. 
Signals with P <  5 ×  10−9 in the meta-analysis of UK Biobank and SpiroMeta, and that had consistent directions of effect but did not meet P <  10−3 in both 
cohorts, were reported as tier 3.
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and GDF5 (a newly implicated gene for a previously reported sig-
nal), and by strengthened eQTL evidence for TGFB2 and MFAP2 
at two previously reported signals. The presence of TGFB2, GDF5 
and SMAD3 in our list of 107 genes led to enrichment of a TGF-β 
superfamily signaling pathway (TGF-Core) and related gene ontol-
ogy terms (Supplementary Table 15).
Functional enrichment analyses. Using stratified LD-score regres-
sion40, we showed that FEV1/FVC and FVC heritability are sig-
nificantly enriched at variants overlapping histone marks that are 
specific to lung, fetal lung, and smooth muscle–containing cell lines. 
SNPs that overlap with H3K4me1 marks that are specific to fetal 
lung correspond to 6.99% of the input SNPs yet explain 57.09% 
(P = 2.85 × 10−25) and 35.84% (P = 4.19 × 10−21) of the SNP-chip 
heritability for FEV1/FVC and FVC, respectively (Supplementary 
Table 16).
We also tested enrichment of (1) FEV1/FVC and (2) FVC SNPs at 
DNase I hypersensitive site hotspots using GARFIELD41 (Methods). 
For FEV1/FVC results, we saw significant enrichment across most 
cell lines with increased fold enrichment in fetal and adult lung, 
fetal muscle and fibroblasts (Supplementary Fig. 4a). For FVC, 
we saw similar broad significant enrichment without evidence of 
increased enrichment in a subset of tissues (Supplementary Fig. 4b), 
suggesting that SNPs influencing FVC may act via more complex 
and broader developmental pathways.
We used DeepSEA42 to identify whether our signals were pre-
dicted to have a chromatin effect in lung-related cell lines. We iden-
tified ten signals (including five new signals) for which the SNP 
with the largest posterior probability of being causal also had a 
significant predicted effect on a DNase I hypersensitive site in lung-
related cells (Supplementary Table 17). This included a new signal 
near SMURF2 (rs11653958).
Drug targets. All 107 putative causal genes were investigated for 
known gene-drug interactions43 (Supplementary Table 18). We 
highlight two examples of new genetic signals implicating targets 
for drugs in development for indications other than COPD. One 
of our new signals is an eQTL for ITGAV. ITGAV encodes a com-
ponent of the α vβ 6 integrin heterodimer, which is inhibited by 
a monoclonal antibody in development for pulmonary fibrosis 
(NCT01371305) and for which the small molecule GSK3008348 
(NCT03069989) is an antagonist44. Integrins have an emerging 
role as local activators of TGFβ and the avb6 integrin heterodimer 
can activate latent TGFβ 45. In our study, the allele associated with 
reduced expression of ITGAV (Supplementary Table 13) was asso-
ciated with increased lung function (Supplementary Table 9), sug-
gesting that inhibitors of α vβ 6 integrin might also have a beneficial 
effect in COPD. Another new signal is associated with expression of 
TNFSF13 (synonym APRIL), which encodes a cytokine of the TNF 
ligand family. Atacicept blocks B cell stimulation by TNFSF13 (as 
well as by BLyS) and reduced systemic lupus erythematosus disease 
activity in a recent phase 2b trial46. In our study, the allele associated 
with decreased expression of TNFSF13 was associated with reduced 
FEV1, indicating that vigilance for pulmonary consequences of 
atacicept may be warranted.
Association with FEV1/FVC and COPD in multiple ancestries. We 
constructed a genetic risk score (GRS) weighted by FEV1/FVC effect 
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Fig. 2 | Strength and direction of association across four lung function traits for 139 novel signals. Signals are in chromosome and genomic position 
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Table 1 | Genes implicated using gene expression data, protein level data and functional annotation
Gene Phenotype Other traits Novel tier/
previous
Sentinel SNP Position (b37) COPD 
risk/alt
Functionally implicated genes
DHDDS (intron) FVC FEV1 Tier 2 rs9438626 1:26,775,367 G/C DHDDSa
DHDDS (3′ -UTR) FEV1 Tier 1 rs12096239 1:26,796,922 C/G HMGN2a, DHDDSa
NEXN (intron) FEV1/FVC Tier 1 rs9661687 1:78,387,270 T/C NEXNa
DENND2D (intron) FEV1/FVC FEV1 Tier 1 rs9970286 1:111,737,398 G/A CEPT1a, CHI3L2a, DRAM2a
C1orf54 (intron) PEF Tier 1 rs11205354 1:150,249,101 C/A MRPS21a, RPRD2a, ECM1b
KRTCAP2 FEV1/FVC Tier1 rs141942982 1: 155153537 T/C THBS4b
RALGPS2 (intron) FEV1 FVC Tier 1 rs4651005 1:178,719,306 C/T ANGPTL1a
LMOD1 (intron) FEV1/FVC Tier 2 rs4309038 1:201,884,647 G/C SHISA4a
ATAD2B (intron) FVC FEV1 Tier 2 rs13009582 2:24,018,480 G/A UBXN2Aa
PKDCC FVC FEV1 Tier 1 rs4952564 2:42,243,850 A/G PKDCCa
ITGAV (intron) FEV1/FVC Tier 1 rs2084448 2:187,530,520 C/T ITGAVa
SPATS2L (intron) FEV1/FVC Tier 2 rs985256 2:201,208,692 C/A SPATS2La
MAB21L4 FVC Tier 1 rs6437219 2:241,844,033 C/T MAB21L4a,c
MIR548G FVC FEV1 Tier 1 rs1610265 3:99,420,192 T/C FILIP1La
BCHE (exon) FEV1/FVC Tier 1 rs1799807 3:165,548,529 C/T BCHEc
BTC (intron) FEV1/FVC FEV1 Tier 1 rs62316310 4:75,676,529 G/A BTCc
LOC100996325 FEV1 FEV1/FVC Tier 1 rs11739847 5:609,661 A/G CEP72c
RNU6-71P FEV1 Tier 1 rs2894837 6:56,336,406 G/A DSTc
JAZF1 (intron) FEV1 FVC, PEF Tier 1 rs1513272 7:28,200,097 C/T JAZF1a
MET (intron) FEV1/FVC Tier 2 rs193686 7:116,431,427 T/C METa
IER5L FEV1 Tier 2 rs967497 9:131,943,843 G/A CRATa, PTPAa, IER5Lc
DOCK9 FEV1/FVC Tier 1 rs11620380 13:99,665,512 A/C DOCK9c
CHAC1 FVC Tier 1 rs4924525 15:41,255,396 A/C INO80a, CHP1a, RAD51a
ATP2A3 FEV1/FVC Tier 1 rs8082036 17:3,882,613 G/C ATP2A3a
PITPNM3 FEV1 Tier 2 rs4796334 17:6,469,793 A/G KIAA0753a,c, TXNDC17a, PITPNM3a
TNFSF12-TNFSF13 FEV1 Tier 2 rs4968200 17:7,448,457 C/G TNFSF13a, SENP3a
NCOR1 (intron) FVC Tier 2 rs34351630 17:16,030,520 C/T ADORA2Ba, TTC19a
ASPSCR1 (intron) FVC FEV1 Tier 1 rs59606152 17:79,952,944 C/T LRRC45c
RMC1 FVC FEV1 Tier 1 rs303752 18:21,074,255 A/G RMC1a
ZFP82 FVC Tier 2 rs2967516 19:36,881,643 A/G ZFP14a, ZFP82a
MFAP2 FEV1/FVC FVC, PEF Previous rs9435733 1:17,308,254 C/T MFAP2a
LOC101929516 FEV1/FVC FEV1, PEF Previous rs755249 1:39,995,074 T/C PABPC4a
TGFB2 PEF Previous rs6604614 1:218,631,452 C/G TGFB2a
TRAF3IP1 FEV1 FEV1/FVC Previous rs6710301 2:239,441,308 C/A ASB1c
SLMAP (intron) FEV1 FVC, FEV1/FVC, 
PEF
Previous rs6445932 3:57,879,611 T/G SLMAPa
RSRC1 (intron) FVC FEV1 Previous rs12634907 3:158,226,886 G/A RSRC1a
GSTCD (intron) FEV1 FVC, FEV1/FVC Previous rs11722225 4:106,766,430 T/C INTS12a
NPNT (intron) FEV1/FVC FEV1, FVC, PEF Previous rs34712979 4:106,819,053 A/G NPNTa,b
AP3B1 (intron) FVC Previous rs425102 5:77,396,400 G/T AP3B1a
SPATA9 FEV1/FVC Previous rs987068 5:95,025,146 C/G RHOBTB3a
P4HA2-AS1 FVC Previous rs3843503 5:131,466,629 A/T SLC22A5a, P4HA2a, C1QTNF5b
CYFIP2 (intron) FEV1/FVC FEV1, PEF Previous rs11134766 5:156,908,317 T/C ADAM19a
ADAM19 (intron) FEV1/FVC FEV1, PEF Previous rs11134789 5:156,944,199 A/C ADAM19a,c
DSP (intron) FEV1/FVC Previous rs2076295 6:7,563,232 T/G DSPa
MIR588 FVC FEV1 Previous rs6918725 6:126,990,392 T/G CENPWa
ADGRG6 (exon) FEV1/FVC FVC, PEF Previous rs17280293 6:142,688,969 A/G ADGRG6c
C1GALT1 (intron) FEV1/FVC Previous rs4318980 7:7,256,490 A/G C1GALT1a
QSOX2 (3′ -UTR) FVC FEV1 Previous rs7024579 9:139,100,413 T/C QSOX2a
Continued
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sizes comprising all 279 sentinel variants, and tested for association 
with FEV1/FVC and GOLD stage 2–4 COPD (FEV1/FVC < 0.7 and 
FEV1 < 80% predicted) in different ancestry groups in UK Biobank, 
and China Kadoorie Biobank (CKB) (Methods and Supplementary 
Table 19). UK Biobank participants of non-European ancestry were 
not included in the discovery analyses. The GRS was associated 
with a significant decrease in lung function and a corresponding 
significant increase in COPD risk in each of the independent ances-
try groups (Fig. 3a).
We tested for a GRS interaction with smoking in individuals 
of European ancestry in UK Biobank47. No statistical interaction 
was seen for FEV1/FVC (interaction term –0.002 per s.d. change 
in GRS, 95% confidence interval (CI): [0.009, 0.005], P = 0.532), 
whereas the findings for COPD were consistent with a slightly 
smaller effect of the GRS in ever smokers (odds ratio (OR) for ever-
smoking-GRS interaction term per s.d. change in GRS 0.96, 95% 
CI: [0.92, 0.99], P = 0.015).
The association of the GRS with COPD susceptibility was addi-
tionally tested in five independent COPD case-control studies 
(Supplementary Table 20 and Methods). Similar effect size estimates 
were seen across each of the five European ancestry studies (Fig. 
3b); in the meta-analysis of these studies (n = 6,979 cases and 3,915 
controls), the OR for COPD per s.d. of the weighted GRS was 1.55 
(95% CI: [1.48, 1.62]), P = 2.87 × 10−75 (Supplementary Table 21). 
The GRS was also associated with COPD in individuals of 
African-American ancestry in COPDGene (P = 8.36 × 10−7), albeit 
with a smaller effect size estimate, OR = 1.26 (95% CI: [1.15, 1.37]).
To aid clinical interpretation, we divided individuals in each of 
the five European-ancestry COPD case-control studies into deciles, 
according to their value of the weighted GRS. The OR for COPD 
in members of the highest GRS decile compared to the lowest GRS 
decile was 4.73 (95% CI: [3.79, 5.90]), P = 3.00 × 10−43 (Fig. 3c and 
Supplementary Table 22). We calculated the population-attributable 
risk fraction (Supplementary Note) and estimated that the propor-
tion of COPD cases attributable to risk scores above the first GRS 
decile was 54.6% (95% CI: [50.6%, 58.4%]).
Incorporation of the GRS into a risk model already comprising 
available clinical information (age, sex, height and pack-years of 
smoking in COPDGene non-Hispanic whites) led to a statistically 
significant (P = 3.33 × 10−10) yet modest increase in the area under 
the curve, from 0.751 to 0.771 (Supplementary Note). Based on our 
estimated GRS relative risk and absolute risk estimates of COPD48, 
we would expect the highest GRS-risk decile group of smokers to 
have an absolute risk of developing COPD by ~70 years of age of 
82.4%, versus 17.4% for the lowest GRS decile (Supplementary Note).
Pleiotropy and phenome-wide association studies. As phenome-
wide association studies (PheWASs) can provide evidence mimick-
ing pharmacological interventions of drug targets in humans and 
informing drug development49, we undertook a PheWAS of 2,411 
Gene Phenotype Other traits Novel tier/
previous
Sentinel SNP Position (b37) COPD 
risk/alt
Functionally implicated genes
DNLZ (intron) FVC Previous rs4073153 9:139,259,349 G/A SNAPC4a, CARD9a, INPP5Ea
CDC123 (intron) FEV1/FVC FEV1, FVC, PEF Previous rs7090277 10:12,278,021 T/A NUDT5a
MYPN (intron) FVC FEV1 Previous rs10998018 10:69,962,954 A/G MYPNc
EML3 (intron) FEV1 FVC Previous rs71490394 11:62,370,155 G/A EEF1Ga, ROM1a,c, EML3a,c
ARHGEF17 (intron) FEV1/FVC FEV1 Previous rs2027761 11:73,036,179 C/T FAM168Aa, ARHGEF17a,c
RAB5B (intron) FEV1 Previous rs1689510 12:56,396,768 C/G CDK2a
LRP1 (intron) FEV1/FVC  PEF Previous rs11172113 12:57,527,283 T/C LRP1a
FGD6 (intron) FEV1/FVC Previous rs113745635 12:95,554,771 T/C FGD6a
RPAP1 FEV1/FVC Previous rs2012453 15:41,840,238 G/A ITPKAa, LTKa, TYRO3a, RPAP1a
AAGAB FVC Previous rs12917612 15:67,491,274 A/C AAGABa, SMAD3a, IQCHa
THSD4 (intron) FEV1/FVC  FEV1, PEF Previous rs1441358 15:71,612,514 G/T THSD4a
IL27 FEV1 Previous rs12446589 16:28,870,962 A/G SBK1a, TUFMa, SGF29a, SULT1A1a, 
SULT1A2a,c, SH2B1a, NPIP87a, 
CLN3a, ATXN2La, EIF3Ca
MMP15 (intron) FEV1/FVC Previous rs11648508 16:58,063,513 G/T MMP15a
SSH2 (intron) FEV1/FVC PEF Previous rs2244592 17:28,072,327 A/G EFCAB5a
FBXL20 (intron) FVC FEV1 Previous rs8069451 17:37,504,933 C/T CDK12a, FBXL20a
MAPT-AS1 FEV1 FVC, PEF Previous rs79412431 17:43,940,021 A/G LRRC37A4Pa, MAPTc
TSEN54 (intron) FEV1 Previous rs9892893 17:73,525,670 G/T CASKIN2a, TSEN54c
LTBP4 (exon) FEV1/FVC PEF Previous rs34093919 19:41,117,300 G/A LTBP4c
ABHD12 (intron) FEV1 Previous rs2236180 20:25,282,608 C/T PYGBa,c
UQCC1 (5′ -UTR) FVC FEV1, PEF Previous rs143384 20:34,025,756 G/A UQCC1a, GDF5a
SLC2A4RG (intron) FVC FEV1 Previous rs4809221 20:62,372,706 A/G LIME1a
SCARF2 (intron) FEV1 FEV1, FVC Previous rs9610955 22:20,790,723 C/G SCARF2c,b
‘Other traits’ column lists the other lung function traits for which the sentinel was associated at P <  5 ×  10−9 in the meta-analysis of UK Biobank and SpiroMeta. ‘COPD risk/alt’ column shows the COPD 
risk allele (i.e., FEV1/FVC reducing) and the alternate (‘alt’) allele. In total, 107 putative causal genes were identified: 8 by both a deleterious variant and an eQTL signal (including KIAA0753 implicated by 
two deleterious variants), 1 (NPNT) by both an eQTL and a pQTL signal, 1 (SCARF2) by both a deleterious variant and a pQTL signal, 13 by a deleterious variant only, 81 by an eQTL signal only and 3 by a 
pQTL signal only. aGenes implicated by eQTL signals: lung eQTL (n =  1,111) and blood eQTL (n =  4,896) data sets and 11 GTEx (V7) tissues were screened: artery aorta (n =  267), artery coronary (n =  152), 
artery tibial (n =  388), colon sigmoid (n =  203), colon transverse (n =  246), esophagus gastroesophageal junction (n =  213), esophagus muscularis (n =  335), lung (n =  383), small intestine terminal ileum 
(n =  122), stomach (n =  237) and whole blood (n =  369); see Supplementary Table 13 for direction of gene expression for the COPD risk (FEV1/FVC reducing) allele. bGenes implicated by pQTL signals: 
pQLT look-up in 3,600 plasma proteins (n up to 3,300). cGenes implicated because they contain a deleterious variant (Supplementary Table 11).
Table 1 | Genes implicated using gene expression data, protein level data and functional annotation (Continued)
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phenotypes in UK Biobank (Methods, Fig. 4 and Supplementary 
Table 23); 226 of the 279 sentinel variants were associated (false 
discovery rate (FDR) < 1%) with one or more traits and diseases 
(excluding quantitative lung function traits). Some 85 of the lung 
function signals were associated with standing height. To investi-
gate whether the genetic association signals for lung function were 
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Fig. 3 | Association of weighted genetic risk score with COPD and FEV1/FVC. a, Association of the weighted genetic risk score (wGRS) with FEV1/FVC 
and COPD in UK Biobank (UKB) and CKB (Supplementary Table 19). Left-hand y-axis, s.d. change in FEV1/FVC per s.d. increase in wGRS (light grey bars, 
n =  total sample size). Right-hand y-axis, the translation of this effect to COPD (GOLD stage 2–4) OR per s.d. increase in wGRS in the same individuals 
for UKB ancestries with > 100 COPD cases (dark grey bars, n =  number of cases plus number of controls). Whiskers represent 95% CI. Some variants 
in the wGRS were discovered in UKB Europeans, therefore UKB Europeans are shown for reference only (far left, discovery sample). All other ancestral 
groups are independent to UKB Europeans. b, OR for COPD per s.d. increase in wGRS in six study groups. COPD was defined using GOLD 2–4 criteria 
(Supplementary Table 21: mean and s.d. of risk scores). The vertical black line indicates the null effect (OR =  1). The point estimate of each study is 
represented by a box proportional to study weight; whiskers represent 95% CI. The diamond represents a fixed-effect meta-analysis of the five European-
ancestry groups, the width of which represents the 95% CI (I2 statistic =  0). c, OR for COPD according to deciles of the wGRS, with decile 1 (the 10% of 
individuals with the lowest GRS) as the reference group. Each point represents a meta-analysis of results for a given comparison (for example, decile 2 
versus reference, or decile 3 versus reference) in five external European-ancestry study groups (COPDGene, ECLIPSE, GenKOLS, SPIROMICS and NETT-
NAS). Deciles were calculated and models were run in each group separately. Error bars show 95% CI (Supplementary Table 22).
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driven by incomplete adjustment for height, we tested for corre-
lation of effects on lung function in UK Biobank and height in a 
meta-analysis of UK Biobank and the GIANT consortium for 246 
of the 279 signals that had a proxy variant in GIANT50; there was 
no significant correlation (Supplementary Fig. 5). Additionally, the 
PheWAS identified associations with body composition measures 
such as fat-free mass (54 SNPs) and hip circumference (40 SNPs), 
as well as muscle strength (32 SNPs, grip strength). Some 114 of 
the 279 SNPs were associated with several quantitative measures 
of blood count, including eosinophil counts and percentages (25 
SNPs). Twenty-five of our SNPs were also associated with asthma 
including 12 SNPs associated with both asthma and eosinophil 
measures (Supplementary Table 24). Eight of these SNPs were in 
LD (r2 > 0.1) with a SNP reported for association with asthma in 
previously published GWASs. We compared our observed effect 
sizes with those estimated after exclusion of all self-reported asthma 
cases and observed similar estimates (Supplementary Fig. 6), 
suggesting that the lung function associations we report are not 
driven by asthma.
We examined the specificity of genetic associations, given the 
potential for this to predict specificity of drug target modification, 
and found that 53 of the 279 signals were associated only with lung 
function and COPD-related traits. In contrast, 3 of our 279 signals 
were associated with > 100 traits across multiple categories—among 
these rs3844313, a known intergenic signal near HLA-DQB1, was 
associated with 163 traits, and also had the strongest signal in the 
PheWAS, which was for association with intestinal malabsorption 
and celiac disease.
In our 279-variant weighted GRS PheWAS analysis 
(Supplementary Table 25), we found association with respiratory 
traits including COPD, chronic bronchitis, emphysema, respira-
tory failure, corticosteroid use and both pediatric and adult-onset 
asthma (Fig. 5a). The GRS was also associated with nonrespiratory 
traits including celiac disease, an intestinal autoimmune disorder 
(Fig. 5b). These pleiotropic effects on risk of autoimmune diseases 
were further confirmed by analysis of previously reported GWASs 
(Methods and Supplementary Table 26), which showed overlapping 
single-variant associations with Crohn’s disease, ulcerative colitis, 
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Fig. 5 | PheWAS with genetic risk score (traits passing FDR 1% threshold). Association of a 279 variant weighted genetic risk score with 2,453 traits 
(FDR <  1%) in UK Biobank (n up to 379,337). In each panel, the category with the strongest association, that is, highest –log10[FDR], is shown first, 
followed by all other associations in that category, ordered by descending order of –log10[FDR]. Sample sizes varied across traits and are available in 
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trait. Trait categories are color coded, and outcomes are denoted with a circular or triangular point, according to whether they were coded as binary 
or quantitative. The sign of the log10[FDR] value is positive where an increase in the risk score (that is, greater risk of COPD, reduced lung function) is 
associated with a positive effect estimate for that trait. *QC refers to spirometry passing European Respiratory Society/American Thoracic Society  
criteria. SR, self-report; HES, hospital episode statistics. a, Associations with respiratory traits. b, Associations with all other traits. ENT, ear, nose and 
throat; FBC, full blood count.
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psoriasis, systemic lupus erythematosus, IgA nephropathy, pediatric 
autoimmune disease and type 1 diabetes.
Discussion
The large sample size of our study, achieved by our refinement of 
the spirometry in UK Biobank and inclusion of the substantially 
expanded SpiroMeta consortium data set, has doubled the yield of 
lung function signals to 279. Fine-mapping of all new and previ-
ously reported signals, together with gene and protein expression 
analyses with improved tissue specificity and stringency, has impli-
cated new genes and pathways, highlighting the importance of cilia 
development, TGF-β signaling via SMAD3, and elastic fibers in the 
etiology of airflow obstruction. Many of the genes and pathways 
reported here contain druggable targets; we highlight examples 
in which the genetic variants mimicking therapeutic modulation 
of targets may have opposing effects on lung function. We have 
developed and applied the first weighted GRS for lung function 
and tested it in independent COPD case-control studies. Our 
GRS shows stronger association and larger effect-size estimates 
than a previous GRS in European-ancestry populations18, as well 
as generalizability to other ancestry groups. We undertook the 
first comprehensive PheWAS for lung function signals, and report 
genetic variants with apparent specificity of effects and others with 
pleiotropic effects that might indicate shared biological pathways 
between different diseases.
For the first time in a GWAS of lung function, we report an 
enrichment of genes involved in ciliogenesis (including KIAA0753, 
CDK2 and CEP72). Defects in primary cilia as a result of highly 
deleterious mutations in essential genes lead to ciliopathies known 
to affect multiple organ systems. We found an enrichment of genes 
with a role in centriolar replication and duplication, core processes 
in primary and motile cilia formation. Mutations in KIAA0753 cause 
the ciliopathies Joubert syndrome and orofaciodigital syndrome28. 
Reduced airway motile cilia function impacting mucus clearance is 
a feature of COPD, but it has not been clear whether this is causal or 
the consequence of damage by external factors such as smoking or 
infection. Our findings suggest that impaired ciliary function might 
be a driver of the disease process. We have previously shown enrich-
ment of rare variants in cilia-related genes in heavy smokers without 
airflow obstruction51.
New signals implicating ITGAV and GDF5, as well as stronger 
support for TGFB2 and MFAP2 as probable causal genes, provide 
new genetic support for the importance of elastic fiber pathways 
in lung function and COPD18. The elastic fibers of the extracellu-
lar matrix are disrupted in COPD52. As the breakdown of elastic 
fibers by neutrophil elastase leads to emphysema in individuals with 
α 1-antitrypsin deficiency, we also assessed the association with the 
SERPINA1 Z allele, which was not associated with FEV1/FVC in our 
study (rs28929474, P = 0.109 in UK Biobank).
Smoking and genetic risk both have important effects on lung 
function and COPD. For lung function, we found no interaction 
between smoking and individual variants, and for FEV1/FVC we 
found no interaction between smoking status and the weighted 
GRS. However, for COPD, a weak smoking-GRS interaction was 
observed. Although the weighted GRS showed a strong association 
with COPD susceptibility and a high attributable risk, we do not 
claim that this would represent an appropriate method of screen-
ing for COPD risk. Importantly, our findings demonstrate the high 
absolute risk among genetically susceptible smokers (82.4% by 
~70 years of age).
We used two complementary study designs to maximize 
sample size for discovery and ensure robustness of findings by 
requiring independent support for association. Furthermore, 
through additional analysis of the spirometry data in UK Biobank 
and substantial expansion of the SpiroMeta consortium, we have 
markedly increased samples sizes to almost seven times those 
included in previous studies. As no lower minor-allele-frequency 
threshold was applied in our analyses, an overall threshold 
of P < 5 × 10−9, as recommended for resequencing analyses of 
European-ancestry individuals23, was applied. We identified the 
largest number of new signals in our more stringent two-stage 
design (tier 1, 99 new signals). Among the signals that we report as 
tier 3 (and did not include in further analyses), all reached P < 10−3 
in UK Biobank and 183 met a less stringent threshold of P < 0.05 
in SpiroMeta.
Our study is the first to investigate genome-wide associations 
with PEF. PEF is determined by various physiological factors 
including lung volume, large airway caliber, elasticity of the lung 
and expiratory muscle strength, is used for monitoring asthma, and 
was incorporated in a recently evaluated clinical score for diagnos-
ing COPD and predicting acute exacerbations of COPD53. Overall, 
133 of the 279 signals were also associated with PEF (P < 10−5) and 
for 15 signals (including 4 new signals), PEF was the most signifi-
cantly associated trait. Notably, a signal near SLC26A9, a known cys-
tic fibrosis modifier gene54, was highly significantly associated with 
PEF in UK Biobank (P = 3.97 × 10−66) and nominally significant in 
SpiroMeta (P = 6.93 × 10−3), with consistent direction of effect, but 
did not meet the tier 2 criteria. This could reflect the limited power 
for PEF in SpiroMeta (up to 24,218 for PEF compared to 79,055 for 
the other traits).
Examining associations of a given genetic variant with a wide 
range of human phenotypes is a valuable tool in therapeutic 
target validation. As in our PheWAS, it can highlight variants 
that show associations with one or more respiratory traits that 
might be expected to demonstrate greater target specificity 
than variants associated with many traits. Additionally, in some 
instances, association with multiple traits may indicate the rel-
evance of drug repurposing. Association of a given SNP with 
multiple traits does not necessarily imply shared etiology, and 
further investigation is warranted. Our GRS PheWAS assesses 
broader genetic overlap between lung function and other traits 
and supports the evidence for some shared genetic determinants 
with autoimmune diseases.
In summary, our study has doubled the number of signals for 
lung function and provides new understanding and resources of 
utility for the development of therapeutics. The 279-variant GRS we 
constructed was associated with a 4.73-fold increased relative risk 
of moderate to severe COPD between highest and lowest deciles, 
such that we would expect > 80% of smokers in the highest genetic-
risk decile to develop COPD. The GRS was also predictive of COPD 
across multiple ancestral groups. Our PheWAS highlights both 
expected and unexpected associations relevant to respiratory and 
other systemic diseases. Investigating the nature of the pleiotropic 
effects of some of these variants will be of benefit for drug target 
identification and validation.
URLs. UK Biobank, http://www.ukbiobank.ac.uk; Ensembl, https://
www.ensembl.org/vep; The Drug-Gene Interaction Database, 
http://www.dgidb.org/downloads; ChEMBL drug indications, 
https://www.ebi.ac.uk/chembl/drug/indications; EBI GWAS cata-
log, https://www.ebi.ac.uk/gwas/; GRASP catalog, https://grasp.
nhlbi.nih.gov/Overview.aspx.
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Methods
Study design overview and rationale. For the two-stage approach, we first 
selected distinct signals of association (defined using conditional analyses) 
with one or more traits achieving P < 5 × 10−9 in UK Biobank only (maximum 
n = 321,047). A threshold of P < 5 × 10−9 was selected to maximize stringency and 
for consistency with currently recommended genome-wide significance thresholds 
for resequencing analyses of European-ancestry individuals23. We reported as 
new those signals that additionally met P < 10−3 in SpiroMeta (effective n > 70% 
of n up to 79,055; see Supplementary Note and Supplementary Fig. 7 for power 
calculations), with consistent directions of effect. We term these tier 1 signals, as 
they meet our highest level of stringency. Methods for conditional analyses and 
determining novelty are described below.
For the one-stage approach, we selected distinct signals of association (defined 
using conditional analyses) with one or more traits reaching P < 5 × 10−9 in the 
meta-analysis of UK Biobank and SpiroMeta (maximum n = 400,102), reporting 
as new those with a consistent direction of effect that additionally met P < 10−3 in 
both UK Biobank and SpiroMeta. We term these signals tier 2, as they meet our 
second-highest level of stringency.
All signals meeting either set of criteria described above, and that had not 
been previously published, were reported as new association signals for lung 
function. Signals that reached P < 5 × 10−9 in the meta-analysis of UK Biobank and 
SpiroMeta, had a consistent direction of effect in UK Biobank and SpiroMeta, and 
that did not reach P < 10−3 in both UK Biobank and SpiroMeta are presented as  
tier 3, and were not included in further analyses.
Data for chromosome X were available for 321,027 European individuals in  
UK Biobank and 38,199 individuals from SpiroMeta (1000 Genomes Project  
Phase 1 imputation)55.
Please see the Life Sciences Reporting Summary.
UK Biobank. The UK Biobank resource is described elsewhere (see URLs). 
Individuals were selected for inclusion in this study if they (1) had complete data 
for age, sex, height and smoking status; (2) had spirometry meeting quality control 
requirements (based on analyses of acceptability, reproducibility and blow curve 
metrics; Supplementary Note); (3) had genome-wide imputed data and (4) were of 
European ancestry based on genetic data (Supplementary Note and Supplementary 
Fig. 1). Genotyping was undertaken using the Affymetrix Axiom UK BiLEVE 
and UK Biobank arrays13. Genotypes were imputed to the Haplotype Reference 
Consortium panel56 (Supplementary Note), and retained if minor allele count 
was ≥ 3 and imputation quality (info) was > 0.5. In total, 321,047 individuals were 
included in our analyses (Supplementary Table 1).
Residuals from linear regression of each trait (FEV1, FVC, FEV1/FVC and 
PEF) against age, age2, sex, height, smoking status (ever or never) and genotyping 
array were ranked and inverse-normal transformed, giving normally distributed 
Z-scores. These Z-scores were used for genome-wide association testing under an 
additive genetic model using BOLT-LMM v2.3 (ref. 20). Principal components were 
not included as BOLT-LMM uses a linear mixed model to account for relatedness 
and fine-scale population structure.
LD score regression implemented in LDSC21 was used to estimate test statistic 
inflation due to any confounding of the association between lung function and 
genotype, e.g., by population stratification. Genomic control was applied, adjusting 
test statistics by LD score regression intercepts: 1.12 for FEV1, 1.14 for FVC, 1.19 
for FEV1/FVC and 1.13 for PEF (Supplementary Fig. 8 and Supplementary Table 27), 
acknowledging that this might be overly conservative for UK Biobank.
SpiroMeta consortium. The SpiroMeta consortium meta-analysis comprised 
79,055 individuals from 22 studies. Some 13 studies (n = 21,436) were imputed to 
the 1000 Genomes Project Phase 1 panel55 (B58C, BHS1&2, three Croatian studies 
(CROATIA-Korcula, CROATIA-Split and CROATIA-Vis), Health 2000, KORA 
F4, KORA S3, LBC1936, NSPHS, ORCADES, SAPALDIA and YFS) and 9 studies 
(n = 61,682) were imputed to the Haplotype Reference Consortium panel57 (EPIC 
(obese cases and population-based studies), GS:SFHS, NFBC1966, NFBC1986, 
PIVUS, SHIP, SHIP-TREND, UKHLS and VIKING). See Supplementary Tables 2 
and 3 for abbreviation definitions, study characteristics, and details of genotyping 
platforms, imputation panels and methods). Measurements of spirometry for each 
study are described in Supplementary Note.
In each study, linear regression models were fitted for each trait (FEV1,  
FEV1/FVC, FVC and, where available, PEF), with adjustment for age, age2, sex and 
height. For studies with unrelated individuals, models were fitted separately in ever 
and never smokers, with additional adjustment for ancestral principal components. 
Studies with related individuals fitted mixed models in all individuals to account 
for relatedness, with ever smoking status as a covariate.
In all studies, residuals were rank-based inverse normal–transformed and 
used as the phenotype for association testing, under an additive genetic model 
(Supplementary Table 3).
In the study-level results, variants were excluded if they had a low minor allele 
count (Supplementary Table 3) or imputation quality (info) of < 0.3. In studies 
of unrelated individuals, ever and never smokers’ results were combined using 
inverse-variance-weighted meta-analysis. Genomic control was applied to all 
study-level results, before combining results across all studies using  
inverse-variance-weighted meta-analysis. LD score regression intercepts for the 
meta-analysis were close to 1.00 (Supplementary Fig. 8 and Supplementary  
Table 27), therefore genomic control was not applied.
Meta-analyses. A total of 19,819,130 variants (imputed or genotyped) in both UK 
Biobank and SpiroMeta were meta-analyzed, using inverse-variance-weighted 
fixed-effect meta-analysis. No further genomic control was applied as LD score 
regression intercepts were close to 1.00 (Supplementary Table 27).
Selection of new signals using conditional analyses. All SNPs ± 1 Mb from each 
sentinel variant were extracted. We performed stepwise conditional analysis to 
select independently associated SNPs within each 2-Mb region, using GCTA58. 
LD was estimated for UK Biobank from the same individuals used in discovery, 
and for SpiroMeta, from an unrelated subset of 48,943 UK Biobank individuals18. 
Secondary signals identified within each 2-Mb region were required to meet tier 
1 or tier 2 criteria (described above) after conditioning on the primary sentinel 
variant. A combined list of distinct lung function signals was then made across 
the four phenotypes, FEV1, FVC, FEV1/FVC and PEF, as follows: where sentinel 
variants for two signals for different phenotypes were in high LD (r2 > 0.5), we 
retained the most significant variant; where two signals were in moderate LD 
(0.1 > r2 > 0.5), we retained variants if, after conditional analysis, they still met the 
tier 1 or tier 2 threshold; for signals in low LD (r2 < 0.1) we retained both variants. 
We then used the same criteria to identify a subset of new signals that were distinct 
from previously published independent signals (see below).
Assessment of previously reported lung function signals. We identified 184 
autosomal signals from previous GWASs of lung function and COPD1,4–14. After LD 
pruning (keeping only signals with LD of r2 < 0.1), we removed 24 nonindependent 
SNPs, leaving 160 previously reported independent signals. Of six previously 
reported signals in the HLA region, we included only the three independent lung 
function HLA signals reported from conditional analysis using all imputed HLA 
genotypes18: AGER (rs2070600), HLA-DQB1 (rs114544105) and near ZNF184 
(rs34864796), leaving 157 autosomal signals.
We confirmed association of previously reported signals in our data if they met 
any of three criteria: (1) the previously reported sentinel was associated (P < 10−5) 
with any lung function trait in UK Biobank; (2) a proxy for the previously 
reported sentinel with r2 > 0.5 was associated (P < 10−5) with any lung function 
trait in UK Biobank; or (3) a proxy for the previously reported sentinel with 
r2 > 0.1 was associated with any lung function trait meeting tier 1 or tier 2 criteria 
(Supplementary Fig. 3).
Effect of genetic risk score on COPD susceptibility in multiple ancestries. 
To test association of all lung function signals with COPD susceptibility, we 
constructed a 279-variant weighted GRS comprising the 139 novel and 140 
previously reported signals; we used the previously reported sentinel SNP for 
published signals. Weights were derived using the FEV1/FVC–decreasing (generally 
COPD risk–increasing) alleles. For previously reported signals (n = 140), effect 
sizes from UK Biobank were used as weights for the 94 signals that were not 
discovered using UK Biobank data. Weights were taken from SpiroMeta for 46 
signals whose discovery included UK Biobank. For novel signals, weights were 
taken from SpiroMeta for two-stage (tier 1) signals (n = 99), and the smallest 
absolute effect size from either UK Biobank or SpiroMeta was used for one-stage 
(tier 2) signals (n = 40) (Supplementary Table 28). This approach was taken to 
derive conservative weights, thus reducing the likelihood of bias by winner’s  
curse. For the weighted GRS the number of risk alleles at each variant was 
multiplied by its weight.
The GRS was first calculated in unrelated individuals (KING kinship 
coefficient of < 0.0884) within six ancestral groups of UK Biobank: Europeans, 
South Asians, Africans, Chinese, mixed African and Europeans, and mixed other 
(total sample of unrelated individuals across six ancestries: 323,001) using PLINK. 
Weights were calculated and allele counts were summed as described above.  
COPD was defined as FEV1/FVC < 0.7 and FEV1 < 80% predicted, that is,  
GOLD stage 2–4 categorization. Associations with the GRS were then tested  
using COPD (in ancestral groups with at least 100 COPD cases) and FEV1/FVC  
as the outcomes.
We also calculated the GRS in individuals from the CKB. Four of the 279 SNPs 
were unavailable in CKB (rs1800888, rs56196860, rs72724130 and rs77672322), 
and for 12 SNPs, proxies were used (minimum r2 = 0.3). Analyses were undertaken 
in all COPD GOLD stage 2–4 cases (FEV1/FVC < 0.7 and FEV1 < 0.8 of the 
predicted value: 6,013 cases and 69,567 controls), against an unbiased set of 
population controls. The GRS was also tested for association with FEV1/FVC in 
CKB (n = 72,796).
Logistic regression of COPD case-control status with the GRS in UK Biobank 
and CKB assumed an additive genetic effect and was adjusted for age, age2, sex, 
height, and smoking (Supplementary Table 19). Ten principal components were 
included in UK Biobank analyses. In CKB, analyses were stratified by geographical 
regions, and then meta-analyzed using an inverse-variance fixed effect model. 
Linear models assessing the association with FEV1/FVC were fitted using the 
transformed outcome used in the main GWAS analysis.
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We then tested association in five European-ancestry COPD case-control 
studies: COPDGene (non-Hispanic white population) (3,068 cases, 2,110 controls), 
ECLIPSE (1,713 cases, 147 controls), GenKOLS (836 cases, 692 controls), 
NETT-NAS (374 cases, 429 controls) and SPIROMICS (988 cases, 537 controls) 
(Supplementary Table 20). We also tested this GRS in the COPDGene African-
American population study (910 cases, 1,556 controls). Logistic regression 
models using COPD as outcome and the GRS as exposure were adjusted for 
age, age2, sex, height, and principal components (Supplementary Table 21 and 
Supplementary Fig. 9). Single-variant associations of the 279 SNPs with COPD are 
in Supplementary Table 29.
Next, we divided individuals in the external COPD case-control studies into 
deciles, according to their values of the weighted GRS (undertaken separately by 
study group). For each of deciles 2–10, logistic models were fitted, comparing 
the risk of COPD for members of the given decile compared to those in the 
lowest decile (i.e., decile 1, the decile containing those with lowest values of the 
weighted GRS). Covariates were the same as for COPD analyses. Results were 
combined across European-ancestry study groups by fixed-effect meta-analysis 
(Supplementary Table 22).
Effects on smoking behavior. As our discovery GWAS in UK Biobank was 
adjusted for ever-smoking status, and not for pack years of smoking (this 
information was missing for 32% of smokers), we evaluated whether any lung 
function association signals might be driven by an association with smoking 
behavior by testing for association with smoking initiation (123,890 ever smokers 
versus 151,706 never smokers) and cigarettes per day (n = 80,015) in UK Biobank 
(see Supplementary Note). We also tested for association with lung function in 
never smokers only (n = 173,658). We excluded signals associated with smoking 
behavior (Supplementary Table 6) but not with lung function in never smokers.
Smoking interaction. For associated variants (new and previously reported), we  
repeated association testing for lung function separately in UK Biobank and SpiroMeta 
(up to 176,701 ever smokers and 197,999 never smokers), and tested for an interaction 
effect with smoking using the Welch test (Supplementary Note). A threshold of 
P < 1.79 × 10−4 (Bonferroni-corrected for 279 tests) indicated significance.
We also tested for interaction between the weighted GRS and smoking within 
303,619 unrelated individuals of European ancestry in UK Biobank, using COPD 
and FEV1/FVC as outcomes (FEV1/FVC was preadjusted for age, age2, sex and 
height, and the residuals transformed as per the main GWAS analysis). For COPD 
(defined as FEV1/FVC < 0.7, and FEV1 < 80% predicted) a logistic model was fitted:
COPD ~ genotyping array + 10 principal 
components + age + age2 + sex + height + smoking status + weighted risk 
score + (smoking status × weighted risk score).
For FEV1/FVC, a linear model was fitted:
FEV1/FVC ~ genotyping array + 10 principal components + smoking 
status + weighted risk score + (smoking status × weighted risk score).
Proportion of variance explained. We calculated the proportion of variance 
explained by the previously reported (n = 140) and new (n = 139) variants 
associated with lung function using the formula:
β∑ −= f f
V
2 (1 )i
n
i i i1
2
where n is the number of variants, fi and βi are the frequency and effect estimate 
of the ith variant, and V is the phenotypic variance (which was always 1 as our 
phenotypes were inverse-normal transformed). We used the same conservative 
effect estimates (β) as GRS weights for the 279 GRS variants, derived from either 
UK Biobank or SpiroMeta effect estimates (described above). Our previously 
published estimate of proportion of variance explained18 used UK Biobank effect 
estimates. We assumed a heritability of 40% (refs. 24,25) to estimate the proportion of 
additive polygenic variance.
Fine-mapping. A Bayesian method59 was used to fine-map lung-function-
associated signals to the set of variants that were 99% probable to contain the 
underlying causal variant (assuming that the causal variant was analyzed). This was 
undertaken for new signals and for previously reported signals reaching P < 10−5 
in UK Biobank. For previously reported signals, the sentinel variant from the 
current UK Biobank analysis was used, instead of the previously reported variant. 
We used a value of 0.04 for W (the variance of the prior distribution of effect sizes) 
in the approximate Bayes factor formula60. Effect sizes and standard errors for 
fine-mapping were obtained from inverse-variance-weighted meta-analysis of UK 
Biobank and SpiroMeta (maximum n = 400,102). Signals in the HLA region were 
not included.
Implication of potentially causal genes. Annotation of deleterious variants. 
Variants in the 99% credible sets were checked for predicted functional effect if 
they were annotated as exonic, splicing, ncRNA_exonic, 5′ -untranslated region  
(5′ -UTR) or 3′ -UTR by ANNOVAR61. We then used SIFT, PolyPhen-2 
(implemented using the Ensembl GRCh37 Variant Effect Predictor, see URLs)  
and FATHMM62 to annotate missense variants, and CADD (also implemented 
using VEP) to annotate noncoding variation. Variants were annotated as 
deleterious if they were labeled deleterious by SIFT, probably damaging or possibly 
damaging by PolyPhen-2, damaging by FATHMM (specifying the “Inherited 
Disease” option of the “Coding Variants” method, and using the “Unweighted” 
prediction algorithm) or had a CADD scaled score ≥ 20 (ref. 18). The union of the 
four methods was taken to establish the number of potentially deleterious variants 
and their unique genes.
Gene expression and protein levels. At 276 of 279 (3 HLA signals excluded)  
signals, the sentinel variant and 99% credible set59 were used to query three  
eQTL resources: lung eQTL (n = 1,111)13, blood eQTL (n = 4,896)63 and  
GTEx (V7; with maximum n = 388, depending on tissue: artery aorta (n = 267), 
artery coronary (n = 152), artery tibial (n = 388), colon sigmoid (n = 203),  
colon transverse (n = 246), esophagus gastroesophageal junction (n = 213), 
esophagus muscularis (n = 335), lung (n = 383), small intestine terminal  
ileum (n = 122), stomach (n = 237) and whole blood (n = 369))64, and one blood 
pQTL resource (n = 3,301)39.
A gene was classified as a putative causal gene if the sentinel SNP or any SNP 
in the respective 99% credible set was associated with expression of this gene or 
its protein levels (FDR < 5% for eQTL, P < 5.03 × 10−8 for pQTL (276 tests at 3,600 
proteins)) and if the GWAS sentinel SNP or any SNP in the respective 99% credible 
set was the variant most strongly associated with expression of the respective gene 
or level of the respective protein (that is, the sentinel eQTL/pQTL SNP) in one or 
more of the eQTL and pQTL data sets.
Pathway analysis. We tested for enrichment of genes identified via functional 
annotation, gene expression or protein level analyses in pathway and gene set 
ontology databases using ConsensusPathDB65. Pathways or gene sets represented 
entirely by genes implicated by the same association signal were excluded. Gene 
sets and pathways with FDR < 5% are reported.
Functional enrichment analyses. We carried out stratified LD score regression to 
identify significant enrichment of heritability at variants overlapping histone marks 
(for example H3K4me1 and H3K4me3) specific to lung, fetal lung and smooth 
muscle–containing (for example, colon or stomach) cell lines, using methods 
specified by Finucane et al40.
We separately selected FEV1/FVC and FVC associated SNPs passing two 
thresholds (P < 5 × 10−5 and P < 5 × 10−9 in the meta-analysis) as input to 
GARFIELD41 to test for enrichment of our signals for 424 DNase I hypersensitive 
site hotspot annotations derived from 55 different tissues in the RoadMap 
Epigenomics and ENCODE projects.
Using DeepSEA42, we analyzed all SNPs in the 99% credible set for predicted 
chromatin effects. We reported effects for any chromatin effect and lung-related 
cell line with an E-value < 0.05 (that is, the expected proportion of SNPs with a 
larger predicted effect based on empirical distributions of predicted effects for 1000 
Genomes SNPs) and an absolute difference in probability of > 0.1 (threshold for 
‘high confidence’) between the reference and alternative allele.
Drug targets. Genes identified as potentially causal using eQTL, pQTL or variant 
annotation were interrogated against the gene-drug interactions table of the Drug-
Gene Interactions Database (see URLs). Drugs were mapped to CHEMBL IDs (see 
URLs), and indications (MeSH headings) were added.
Phenome-wide association studies. To identify whether the 279 signals were 
associated with other traits and diseases, the weighted GRS was calculated in up 
to 379,337 UK Biobank samples, and a PheWAS was performed, with the GRS as 
the exposure. Traits included UK Biobank baseline measures (from questionnaires 
and physical measures), self-reported medication usage, and operative procedures, 
as well as those captured in Office of Population Censuses and Surveys codes 
from the electronic health record. We also included self-reported disease variables 
and those from hospital episode statistics (ICD-10 codes truncated to three-
character codes and combined in block and chapter groups), combining these 
where possible to maximize power. The GRS analysis included 2,453 traits, and the 
single-variant analysis contained 2,411 traits (traits with > 200 cases were included 
for the single-variant PheWAS, whereas traits with > 50 cases were included in 
the GRS PheWAS). Analyses were conducted in unrelated European-ancestry 
individuals (KING kinship coefficient < 0.0442), and were adjusted for age, sex, 
genotyping array and ten principal components. Logistic and linear models were 
fitted for binary and quantitative outcomes, respectively. FDRs were calculated 
according to the number of traits in the GRS and single-variant PheWAS (2,453 or 
2,411, respectively).
In addition, the sentinel variants 99% credible set variants were queried against 
the GWAS catalog66 (see URLs) and GRASP67 (see URLs) for associations at 
P < 5 × 10−8. Associations relating to methylation, expression, metabolite or protein 
levels, lung function or COPD were not included.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
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Data availability
SpiroMeta GWAS summary statistics and UK Biobank GWAS summary statistics 
are available online via LD-Hub (http://ldsc.broadinstitute.org/ldhub/). Single-
variant PheWAS results are available by request to the corresponding authors. The 
newly derived spirometry variables are available from UK Biobank (http://www.
ukbiobank.ac.uk/).
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